Cancer immunotherapy by disrupting PD-1/PD-L1 signaling | Patent Number 10308714

US 10308714 B2
Application Number16024340
Publication NumberUS 20180319887 A1
Pendency11 months, 10 days
Filled DateJun 29, 2018
Priority DateMay 15, 2012
Publication DateNov 8, 2018
Expiration DateMay 14, 2032
Inventor/ApplicantsMaria Jure-Kunkel
Xi-Tao Wang
Jon M. Wigginton
John P. Cogswell
Stacie M. Goldberg
Ashok K. Gupta
ExaminesOUSPENSKI, ILIA I
Art Unit1644
Technology Center1600
Assignments
Bristol Myers Squibb
Current
Bristol Myers Squibb
Original
Law Firm
You must be logged in to view
Login
Attorneys
Subscription-Only
View Concierge Program
See the invalidated claims, subscribe to our Concierge Program.
View Concierge Program
Patent Prosecution report image

Empower your practice with Patexia Publication Prosecution IP Module.

Get access to our exclusive rankings and unlock powerful data.
Check our Latest ReportPurchase IP Module

Looking for a Publication Attorney?

Get in touch with our team or create your account to start exploring a network of over 120K attorneys.